Literature DB >> 28989092

Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes.

Ming-Wai Yeung1, Grace Lai-Hung Wong2, Kai Chow Choi3, Andrea On-Yan Luk4, Raymond Kwok1, Sally She-Ting Shu1, Anthony Wing-Hung Chan1, Eric Siu Him Lau1, Ronald Ching Wan Ma1, Henry Lik-Yuen Chan2, Juliana Chung-Ngor Chan4, Vincent Wai-Sun Wong5, Alice Pik-Shan Kong6.   

Abstract

BACKGROUND & AIMS: Increasing evidence suggests that non-alcoholic fatty liver disease (NAFLD) may be an independent risk factor for chronic kidney disease (CKD). Given the high prevalence of NAFLD among patients with diabetes who are also at risk of CKD, we aimed to investigate the association between NAFLD and albuminuria, a marker commonly found in diabetic nephropathy.
METHODS: This study included a cohort of Chinese patients with type 2 diabetes from the Hong Kong Diabetes Registry recruited between March 2013 and May 2014. Liver stiffness measurement (LSM), with probe-specific cut-offs, was used to detect advanced liver fibrosis. While controlled attenuation parameter (CAP) was used to assess liver steatosis using transient elastography.
RESULTS: A total of 1,763 Chinese patients with type 2 diabetes were recruited in this analysis. The mean (standard deviation) age and duration of diabetes were 60.7 (11.5) years and 10.8 (8.5) years, respectively. The prevalence of albuminuria was higher in diabetic patients with liver steatosis and those with advanced fibrosis (no NAFLD vs. liver steatosis vs. advanced fibrosis: 41.4% vs. 46.2% vs. 64.2%, p <0.001). After adjustment for potential confounders including glycated hemoglobin, hypertension and body mass index, advanced fibrosis, but not liver steatosis, was associated with increased risk of albuminuria (odds ratio [OR] 1.52; 95% confidence interval [CI] 1.02-2.28; p = 0.039) in patients with eGFR ≥60 ml/min/1.73 m2. The odds of albuminuria increased with greater severity of liver fibrosis in a dose dependent manner, with the highest odds observed in patients with LSM scores ≥11.5 kPa assessed by M probe or ≥11.0 kPa assessed by XL probe (adjusted OR 1.53; 95% CI 1.07-2.20; p = 0.021).
CONCLUSIONS: Advanced liver fibrosis, but not steatosis, is independently associated with albuminuria in Chinese patients with type 2 diabetes. Attention should be paid to liver fibrosis in patients with obesity and type 2 diabetes complicated with albuminuria. LAY
SUMMARY: In this study, we assessed the link between non-alcoholic fatty liver disease (NAFLD) and albuminuria in a cohort of 1,763 Chinese patients with type 2 diabetes. This study shows that advanced liver fibrosis, a severe form of NAFLD, was independently associated with increased risk of albuminuria. The risk of albuminuria increased with greater severity of liver fibrosis.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Albuminuria; Diabetes mellitus; Diabetic nephropathies; Liver fibrosis; Non-alcoholic fatty liver disease; Transient elastography; Type 2

Year:  2017        PMID: 28989092     DOI: 10.1016/j.jhep.2017.09.020

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  22 in total

Review 1.  Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease.

Authors:  Mehmet Kanbay; Mustafa C Bulbul; Sidar Copur; Baris Afsar; Alan A Sag; Dimitrie Siriopol; Masanari Kuwabara; Silvia Badarau; Adrian Covic; Alberto Ortiz
Journal:  J Nephrol       Date:  2020-05-21       Impact factor: 3.902

2.  FIB-4 index-based surveillance for advanced liver fibrosis in diabetes patients.

Authors:  Nozomi Kawata; Hirokazu Takahashi; Shinji Iwane; Kanako Inoue; Motoyasu Kojima; Michiko Kohno; Kenichi Tanaka; Hitoe Mori; Hiroshi Isoda; Satoshi Oeda; Yayoi Matsuda; Yoshiaki Egashira; Jyunichi Nojiri; Hiroyuki Irie; Yuichiro Eguchi; Keizo Anzai
Journal:  Diabetol Int       Date:  2020-07-09

3.  Synergistic effects of liver fibrosis and sarcopenia on endothelial dysfunction and arterial stiffness in patients with type 2 diabetes.

Authors:  Teruo Jojima; Hidetaka Kurai; Dai Tanuma; Hayato Kajitani; Masato Kase; Yuiko Inoue; Shintaro Sakurai; Toshie Iijima; Takuya Tomaru; Isao Usui; Yoshimasa Aso
Journal:  Int J Cardiol Heart Vasc       Date:  2022-06-16

Review 4.  Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect.

Authors:  Rajiv Heda; Masahiko Yazawa; Michelle Shi; Madhu Bhaskaran; Fuad Zain Aloor; Paul J Thuluvath; Sanjaya K Satapathy
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

5.  High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes.

Authors:  Haruka Saito; Hayato Tanabe; Akihiro Kudo; Noritaka Machii; Moritake Higa; Satoshi Yamaguchi; Gulinu Maimaituxun; Kazumichi Abe; Atsushi Takahashi; Kenichi Tanaka; Koichi Asahi; Hiroaki Masuzaki; Hiromasa Ohira; Junichiro J Kazama; Michio Shimabukuro
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

Review 6.  Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges.

Authors:  Jean-François Dufour; Cyrielle Caussy; Rohit Loomba
Journal:  Gut       Date:  2020-05-07       Impact factor: 23.059

Review 7.  Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?

Authors:  Carolina M Perdomo; Nuria Garcia-Fernandez; Javier Escalada
Journal:  J Clin Med       Date:  2021-05-10       Impact factor: 4.241

8.  Liver fat content is independently associated with microalbuminuria in a normotensive, euglycaemic Chinese population: a community-based, cross-sectional study.

Authors:  Xiaoming Li; Mingfeng Xia; Hui Ma; Yu Hu; Hongmei Yan; Wanyuan He; Huandong Lin; Nai Qing Zhao; Jian Gao; Xin Gao
Journal:  BMJ Open       Date:  2021-06-29       Impact factor: 2.692

9.  Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study.

Authors:  Xinrong Zhang; Vincent Wai-Sun Wong; Terry Cheuk-Fung Yip; Yee-Kit Tse; Lilian Yan Liang; Vicki Wing-Ki Hui; Guan-Lin Li; Henry Lik-Yuen Chan; Grace Lai-Hung Wong
Journal:  Hepatol Commun       Date:  2021-03-21

10.  Serum levels of mac-2 binding protein are associated with diabetic microangiopathy and macroangiopathy in people with type 2 diabetes.

Authors:  Yoshitaka Hashimoto; Masahide Hamaguchi; Ayumi Kaji; Ryosuke Sakai; Noriyuki Kitagawa; Michiaki Fukui
Journal:  BMJ Open Diabetes Res Care       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.